ArticleCirculation reports2026
Angioscopy-Guided Excimer Laser Atherectomy in Femoropopliteal In-Stent Occlusions.
Article in Circulation reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: In-stent occlusions in femoropopliteal lesions (FP-ISOs) remain a significant clinical issue. Excimer laser atherectomy (ELA) can ablate tissue, including thrombi, and may therefore be effective in FP-ISOs, which frequently contain both thrombi and neointimal hyperplasia. Angioscopy can directly visualize the stent lumen, making it useful for distinguishing thrombi from neointimal hyperplasia. Here, we investigated whether angioscopy-guided ELA was useful for FP-ISOs. Methods and Results: We studied 10 consecutive patients with FP-ISO who underwent endovascular therapy (EVT) with ELA between August 2020 and May 2023. Based on preprocedural angioscopy, patients were divided into 2 groups (n=5 in each): M (thrombi <70% of lesion length) and S (thrombi ≥70%). Outcomes, including Thrombolysis in Myocardial Infarction (TIMI) flow grade and major adverse events (MAE; restenosis, amputation, and death) were compared. There were no significant differences between the 2 groups in TIMI grade 3 flow just after EVT or in the ankle-brachial pressure index 1 month after EVT. Clinical outcomes after ELA were similar between the M and S groups (6-month patency: 60% vs. 80%, respectively [P=0.49]; MAE rate: 40% vs. 60%, respectively [P=0.53]). Five patients receiving direct oral anticoagulants (DOACs) had no events. Conclusions: ELA effectively vaporized thrombi in FP-ISOs, achieving comparable outcomes regardless of thrombus burden. Angioscopy-guided ELA, particularly combined with DOAC therapy, may represent a useful strategy for managing FP-ISOs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.